Articles On Starpharma Holdings (ASX:SPL)

Starpharma (SPL) signs an agreement with Hengan Pharmacare for the sale and distribution of its nasal spray product, VIRALEZE, in Hong Kong and MacauThe agreement will last for an initial two years and will see Starpharma supply VIRALEZE to...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

The ASX 200 is vacillating Small caps are down over 1.3% Demetallica is a great name and it’s up 40% on takeover talk   The benchmark ASX 200 is flat as on Monday. The ASX Emerging Companies (XEC) index has lost 1.3%. REITs and Gold are h...

Starpharma (SPL) presents promising anti-tumour activity data in prostate cancer at the European Society of Medical Oncology (ESMO) Congress in ParisThe data shows DEP cabazitaxel has a number of key advantages which included superior effic...

Starpharma (ASX:SPL) has been announced as the winner of the ‘Most Significant Commercial Outcome’ award following the completion of a Biomedical Translation Bridge program backed by the federal government’s Medical Research Future...

Starpharma (SPL) signs a new DEP research agreement with MSD, the trade name of Merck Sharp & Dohme Under this agreement, Starpharma will design and synthesise a number of DEP dendrimer conjugates for MSD to test and characterise This...

Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and charact...

Starpharma (SPL) confirms its VIRALEZE antiviral nasal spray demonstrates a high level of protection against the infectious SARS-CoV-2 Omicron variant In the study, all the test animals were treated with VIRALEZE in vivo in a humanised mou...

After a brutal start to this Friday’s trading session, the All Ordinaries Index (ASX: XAO) has recovered somewhat. At the time of writing, the All Ords is still down by 0.72% at around 6,800 points after going as low as 6,733 points this m...

Starpharma (SPL) relaunches its VIRALEZE nasal spray with LloydsPharmacy in the United Kingdom VIRALEZE will be supplied exclusively to LloydsPharmacy under its existing sales and distribution agreements LloydsPharmacy is one of the larges...

Cann Group’s Mildura facility has been granted GMP licence Paradigm receives patent application acceptance by IP Australia Starpharma to relaunch VIRALZEE with LloydsPharmacy in the UK Cannabis company Cann Group (ASX:CAN) rose 17% this m...

The Starpharma Holdings Ltd (ASX: SPL) share price has jumped out of the gates and is trading higher on Thursday. At the time of writing, investors are bidding Starpharma 5% higher to 70 cents apiece. Support comes following a company a...

Starpharma (ASX:SPL) has announced that VIRALEZE nasal spray has been relaunched by LloydsPharmacy in the UK.

Starpharma (ASX:SPL) has signed an expanded DEP research agreement with Genentech, a member of the Roche Group, to evaluate additional DEP drug conjugates.

ShareCafeLunch Report: 27 June, 2022 by Lauren Evans   The Australian sharemarket has rallied this morning with all eleven sectors in the green. Materials are leading the pack, up 2.6 per cent, followed by energy, up 2.4 per cent. The secto...

Starpharma (SPL) expands its research agreement with Genentech for its drug delivery technology, DEP The initial agreement was signed in December 2021 and involves Starpharma designing and synthesising dendrimer-based drug conjugates for G...

When is a medicine actually a medical device? The question has been more than academic for Starpharma (ASX:SPL), which ran into a spot of bother with Australia’s Therapeutic Goods Administration (TGA) as to what category its anti-viral nasa...

Starpharma (ASX:SPL) says SPL7013, the antiviral agent in VIRALEZE nasal spray, achieved 95 per cent and 99.7 per cent reduction in viral infectivity against two significant types of influenza virus, A and B, respectively, in viruci...

Starpharma’s (SPL) antiviral agent achieves up to 99.7 per cent reduction in viral activity against two types of influenzas virus The company’s antiviral agent in its VIRALEZE nasal spray achieved a 95 per cent and 99.7 per cent reduction...

ShareCafeWebinar Recap – MX1, SPL, MAP, RFL & RAP Catch up on the full webinar with presentations from Micro-X (ASX: MX1), Starpharma (ASX: SPL), Microba Life Sciences (ASX: MAP), RLF AgTech (ASX: RFL) & ResApp (ASX: RAP) Webinar R...

ShareCafeStarpharma (ASX: SPL) – Webinar Presentation Dr Jackie Fairley – CEO – Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical,...

Starpharma (SPL) will relaunch antiviral nasal spray VIRALEZE in the UK following the resolution of queries raised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) In June 2021, Starpharma’s UK retail partner LloydsPhar...

Cann Group gets the OK in the UK for its CBD food supplements Starpharma to relaunch VIRALEZE in the UK Creso expands to LATAM Cann Group gets OK in the UK Cannabis company Cann Group (ASX:CAN) has received the green light from the UK FSA...

The Starpharma Holdings Limited (ASX: SPL) share price is up 6% following a company announcement to the market this morning. Starpharma has announced it will relaunch its VIRALEZE antiviral nasal spray in the UK after resolving issues rai...

Highlights Incannex’s preliminary assessment of proof-of-concept trial data has indicated efficacy and good safety characteristics of IHL-42X. The data highlighted substantial reduction in AHI, meeting the expectations. Average of low...

Plenty of ASX healthcare shares fell to 52-week lows today. The industry has not been immune to the ASX share market selloff. There is ongoing volatility with investors keeping an on the Russian conflict with Ukraine, the sanctions and the...

Highlights The ASX 200 snapped its 5 day winning streak today, was down 0.6% to close at 7110. Fears over Russian shelling at Europe's biggest nuclear plant in Ukraine weighed on the global market sentiment today. Investors globally r...

Shares in Starpharma Holdings Limited (ASX: SPH) are on the move today after the company released a market sensitive announcement. At the time of writing, the Starpharma share price is down 7.87% at 82 cents. The announcement relates to a...

Highlights The ASX 200 plunged 0.59% in the first 15 minutes of opening trade. Wall Street's main indices continued their volatile session on Thursday, ending in the red. The IT sector is leading the fall with a 2.62% cut. The Aus...

Starpharma (ASX:SPL) has announced that its Australian developed VIRALEZE antiviral nasal spray achieved the maximum possible virucidal effect against the highly transmissible Omicron variant of SARS-CoV-2. 

The antiviral agent in VIRALEZE antiviral nasal spray, SPL7013, achieved >99.5% reduction of virus infectivity (the maximal possible reduction) against the highly contagious Omicron variant of SARS-CoV-2 SPL7013 showed potent antivir...

Starpharma’s (SPL) antiviral nasal spray achieves a greater than 99.5 per cent reduction of virus infectivity against the Omicron variant of SARS-CoV-2 The antiviral agent in VIRALEZE reached the maximum possible reduction of virus infecti...

Shares in Starpharma Holdings Ltd (ASX: SPL) are cruising higher today and now trade 4% in the green at 92 cents apiece. Investors are responding positively to a company announcement regarding its lead drug candidate Viraleze in the fight...

Australian company Starpharma (ASX:SPL) has announced a strong result for the six months to the end of 2021 headlined by strong revenue growth and new commercialisation agreements.

The Starpharma Holdings Ltd (ASX: SPH) share priced closed in the red on Monday after the company released its interim report and financial results for the half-year ended 31 December 2021. Starpharma shares finished the day 5% down at 98....

The ASX 200 Health Index (XHJ) has fallen by 1.26% at the time of writing, compared to the broader index which is down by 0.12%. Medical device company OncoSil Medical (ASX:OSL) surged as high as 25% up today, after its device was granted a...

Starpharma (SPL) signs a deal for its antiviral nasal spray to be available for purchase across nine new countries Through a five-year sales and distribution agreement, VIRALEZE will be available for purchase in Saudi Arabia and eight othe...

Starpharma (SPL) records $1.8 million in receipts from customers for the December quarter, primarily due to the launch of VIRALEZE in Vietnam VIRALEZE launched in Vietnam in December with the product to be distributed by Truong Bao Land In...

Starpharma (SPL) receives a $7.7 million research and development tax incentive refund The refund falls under the Australian Federal Government’s R&D Tax Incentive Scheme The funds were granted in relation to the company’s activities d...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Starpharma (ASX:SPL) has signed a commercial arrangement for its antiviral nasal spray Viraleze in Vietnam with orders in excess of 2 million since late October.

The Starpharma Holdings Ltd (ASX: SPL) share price is lifting this afternoon after a bumpy morning of trading. This follows the company release of a sales update today on an anti-viral product against COVID-19. At the time of writing, th...

Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totalling more than $2 million for Vietnam On December 1, the company announced its nasal spray was registered for sale in Vietnam with a formal launch att...

The Starpharma Holdings Ltd (ASX: SPL) share price is soaring following the company announcement of a partnership agreement. At the time of writing, the dendrimer product developer’s shares are up 6.11% to $1.215 apiece. It’s worth noting...

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

Starpharma (SPL) signs an exploratory Dendrimer Drug Delivery (DEP) research agreement with US Biopharma company, Genentech Genetech has an initial focus on evaluating DEP, dendrimer-based drug conjugates Starpharma’s dendrimer-based drug...

The Starpharma Holdings Limited (ASX: SPL) share price edged higher today following the launch of Viraleze in Vietnam this week. Viraleze is an antiviral nasal spray that has been shown to deactivate a broad spectrum of respiratory/cold vi...

03 Dec 2021 - Starpharam (ASX:SPL) has signed an ongoing agreement for the distribution of the VIRALEZE antiviral nasal spray in Vietnam.

The ASX 200 Health Index (XHJ) is down by 0.67% at the time of writing, compared to the broader index which is up by 0.47%. Alcidion Group (ASX:ALC) rose nearly 8% this morning, after revealing that it was a member of a consortium awarded a...

Starpharma (SPL) has signed an ongoing distribution arrangement to launch its VIRALEZE antiviral nasal spray in Vietnam The deal involves a minimum commitment of at least one million units of VIRALEZE in the first year, and will see the sp...